Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1223467

Cover Image

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1223467

MEA Kidney Cancer Diagnostics Market - Industry Trends and Forecast to 2030

PUBLISHED:
PAGES: 334 Pages
DELIVERY TIME: Inquiry
SELECT AN OPTION
PDF (Single User License) - Printable/Downloadable
USD 3500
PDF (Enterprise License) - Printable/Downloadable
USD 4200

Add to Cart

Middle East and Africa Kidney Cancer Diagnostics Market is projected to register a CAGR of 4.6% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation

Middle East and Africa Kidney Cancer Diagnostics Market, By Test Type (Imaging, Biomarker Test, Blood Test, Biopsy, Genetic Test, and Others), Cancer Stages (Stage I, Stage II, Stage III, and Stage IV), Tumor Type (Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, and Non-Clear Cell Renal Cell Carcinoma), Product (Platform-Based Products, Instrument based products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales and Others), Country (South Africa, Saudi Arabia, Bahrain, UAE, Kuwait, Oman, Qatar, Egypt, Israel, and the Rest of Middle East and Africa), Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the kidney cancer diagnostics market are:

Rising healthcare expenditure for better health services

Growing demand for better quality healthcare

Growing prevalence of kidney cancer

Market Players

Some of the key market players for Middle East and Africa kidney cancer diagnostics market are listed below:

BD

BioVendor R&D

Canon Medical Systems Corporation

CENTOGENE N.V.

FUJIFILM Corporation

GeneDx,LLC

Illumina, Inc.

Invitae Corporation

Koninklijke Philips N.V.

Laboratory Corporation of America Holdings

Myriad Genetics, Inc.

Qiagen

Seimens Healthcare GmbH

Thermo Fisher Scientific Inc.

TABLE OF CONTENTS

1 INTRODUCTION 84

  • 1.1 OBJECTIVES OF THE STUDY 84
  • 1.2 MARKET DEFINITION 84
  • 1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET 84
  • 1.4 CURRENCY AND PRICING 86
  • 1.5 LIMITATIONS 87
  • 1.6 MARKETS COVERED 87

2 MARKET SEGMENTATION 91

  • 2.1 MARKETS COVERED 91
  • 2.2 GEOGRAPHICAL SCOPE 92
  • 2.3 YEARS CONSIDERED FOR THE STUDY 93
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL 94
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 97
  • 2.6 MULTIVARIATE MODELLING 98
  • 2.7 MARKET APPLICATION COVERAGE GRID 99
  • 2.8 TEST TYPE LIFELINE CURVE 100
  • 2.9 DBMR MARKET POSITION GRID 101
  • 2.10 VENDOR SHARE ANALYSIS 102
  • 2.11 SECONDARY SOURCES 103
  • 2.12 ASSUMPTIONS 103

3 EXECUTIVE SUMMARY 104

4 PREMIUM INSIGHTS 107

  • 4.1 PESTEL ANALYSIS 108
  • 4.2 PORTER'S 5 FORCES 109
  • 4.3 EPIDEMIOLOGY 110
    • 4.3.1 KIDNEY CANCER INCIDENCES, 2020, BY BOTH SEXES 111
    • 4.3.2 KIDNEY CANCER MORTALITY, 2020, BY BOTH SEXES 111

5 INDUSTRY INSIGHTS 112

6 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, REGULATIONS 114

7 MARKET OVERVIEW 117

  • 7.1 DRIVERS 119
    • 7.1.1 GROWING PREVALENCE OF KIDNEY CANCER 119
    • 7.1.2 INCREASE IN DIAGNOSTIC PROCEDURES FOR KIDNEY CANCER 121
    • 7.1.3 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 122
    • 7.1.4 RISING AWARENESS TOWARDS KIDNEY CANCER 122
  • 7.2 RESTRAINTS 123
    • 7.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF KIDNEY CANCER DIAGNOSTIC PRODUCTS 123
    • 7.2.2 TISSUE DAMAGE DUE TO HIGH RADIATION EXPOSURE FROM IMAGING TESTS 124
  • 7.3 OPPORTUNITIES 124
    • 7.3.1 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 124
    • 7.3.2 GOVERNMENT INITIATIVES TOWARD KIDNEY CANCER DIAGNOSTICS 125
    • 7.3.3 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE 125
    • 7.3.4 INCREASED DEMAND FOR NON-INVASIVE TESTING METHODS 126
  • 7.4 CHALLENGES 126
    • 7.4.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 126
    • 7.4.2 HIGH COST OF DIAGNOSTICS PROCEDURE FOR KIDNEY CANCERS 127

8 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE 128

  • 8.1 OVERVIEW 129
  • 8.2 IMAGING 133
    • 8.2.1 COMPUTED TOMOGRAPHY 134
    • 8.2.2 ULTRASOUND 134
    • 8.2.3 MAGNETIC RESONANCE IMAGING (MRI) 134
    • 8.2.4 ANGIOGRAPHY 134
    • 8.2.5 X-RAY 134
    • 8.2.6 OTHERS 134
  • 8.3 BLOOD TEST 134
  • 8.4 BIOPSY 135
    • 8.4.1 FINE NEEDLE ASPIRATION 136
    • 8.4.2 NEEDLE CORE BIOPSY 136
  • 8.5 BIOMARKER TEST 136
    • 8.5.1 AQUAPORIN 1 (AQP1) 138
    • 8.5.2 PERILIPIN (PLIN2) 138
    • 8.5.3 N-METHYLTRANSFERASE (NMNT) 138
    • 8.5.4 L-PLASTIN (LCP-1) 138
    • 8.5.5 NM23A 138
  • 8.6 GENETIC TEST 138
  • 8.7 OTHERS 139

9 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE 141

  • 9.1 OVERVIEW 142
  • 9.2 STAGE I 145
  • 9.3 STAGE II 145
  • 9.4 STAGE III 146
  • 9.5 STAGE IV 147

10 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE 148

  • 10.1 OVERVIEW 149
  • 10.2 RENAL CELL CARCINOMA 153
    • 10.2.1 IMAGING 154
    • 10.2.2 BLOOD TEST 154
    • 10.2.3 BIOPSY 154
    • 10.2.4 BIOMARKER TEST 154
    • 10.2.5 GENETIC TEST 154
    • 10.2.6 OTHERS 154
  • 10.3 CLEAR CELL RENAL CELL CARCINOMA 154
    • 10.3.1 IMAGING 156
    • 10.3.2 BLOOD TEST 156
    • 10.3.3 BIOPSY 156
    • 10.3.4 BIOMARKER TEST 156
    • 10.3.5 GENETIC TEST 156
    • 10.3.6 OTHERS 156
  • 10.4 NON CLEAR CELL RENAL CELL CARCINOMA 156
    • 10.4.1 PAPILLARY RENAL CELL CARCINOMA 157
      • 10.4.1.1 IMAGING 158
      • 10.4.1.2 BLOOD TEST 158
      • 10.4.1.3 BIOPSY 158
      • 10.4.1.4 BIOMARKER TEST 158
      • 10.4.1.5 GENETIC TEST 158
      • 10.4.1.6 OTHERS 158
    • 10.4.2 CHROMOPHOBE RENAL CELL CARCINOMA 158
      • 10.4.2.1 IMAGING 159
      • 10.4.2.2 BLOOD TEST 159
      • 10.4.2.3 BIOPSY 159
      • 10.4.2.4 BIOMARKER TEST 159
      • 10.4.2.5 GENETIC TEST 159
      • 10.4.2.6 OTHERS 159

11 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT 160

  • 11.1 OVERVIEW 161
  • 11.2 INSTRUMENT BASED PRODUCTS 165
    • 11.2.1 IMAGING 166
    • 11.2.2 BIOPSY 166
  • 11.3 PLATFORM BASED PRODUCTS 166
    • 11.3.1 NEXT GENERATION SEQUENCING 168
    • 11.3.2 MICROARRAYS 168
    • 11.3.3 PCR 169
    • 11.3.4 OTHERS 169
  • 11.4 KITS AND REAGENTS 169
    • 11.4.1 RENAL CANCER PANELS 171
    • 11.4.2 RENAL CANCER ANTIBODIES 171
  • 11.5 OTHER CONSUMABLES 171

12 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY 172

  • 12.1 OVERVIEW 173
  • 12.2 FLUORESCENT IN SITU HYBRIDIZATION 176
  • 12.3 NEXT GENERATION SEQUENCING 176
  • 12.4 FLUORIMMUNOASSAY 177
  • 12.5 COMPARATIVE GENOMIC HYBRIDIZATION 178
  • 12.6 IMMUNOHISTOCHEMICAL 179
  • 12.7 OTHERS 179

13 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION 181

  • 13.1 OVERVIEW 182
  • 13.2 SCREENING 185
    • 13.2.1 INSTRUMENT BASED PRODUCTS 186
    • 13.2.2 PLATFORM BASED PRODUCTS 186
    • 13.2.3 KITS AND REAGENTS 186
    • 13.2.4 OTHER CONSUMABLES 186
  • 13.3 DIAGNOSTIC AND PREDICTIVE 186
    • 13.3.1 INSTRUMENT BASED PRODUCTS 187
    • 13.3.2 PLATFORM BASED PRODUCTS 187
    • 13.3.3 KITS AND REAGENTS 187
    • 13.3.4 OTHER CONSUMABLES 187
  • 13.4 PROGNOSTIC 188
    • 13.4.1 INSTRUMENT BASED PRODUCTS 189
    • 13.4.2 PLATFORM BASED PRODUCTS 189
    • 13.4.3 KITS AND REAGENTS 189
    • 13.4.4 OTHER CONSUMABLES 189
  • 13.5 RESEARCH 189
    • 13.5.1 INSTRUMENT BASED PRODUCTS 190
    • 13.5.2 PLATFORM BASED PRODUCTS 190
    • 13.5.3 KITS AND REAGENTS 190
    • 13.5.4 OTHER CONSUMABLES 191

14 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER 192

  • 14.1 OVERVIEW 193
  • 14.2 HOSPITALS 196
  • 14.3 DIAGNOSTIC CENTERS 196
  • 14.4 CANCER RESEARCH CENTERS 197
  • 14.5 ACADEMIC INSTITUTES 198
  • 14.6 AMBULATORY SURGICAL CENTERS 198
  • 14.7 OTHERS 199

15 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 200

  • 15.1 OVERVIEW 201
  • 15.2 DIRECT TENDER 204
  • 15.3 RETAIL SALES 204
  • 15.4 OTHERS 205

16 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION 206

  • 16.1 MIDDLE EAST AND AFRICA 207
    • 16.1.1 SOUTH AFRICA 220
    • 16.1.2 SAUDI ARABIA 227
    • 16.1.3 BAHRAIN 235
    • 16.1.4 U.A.E. 242
    • 16.1.5 EGYPT 250
    • 16.1.6 ISRAEL 258
    • 16.1.7 KUWAIT 266
    • 16.1.8 OMAN 274
    • 16.1.9 QATAR 282
    • 16.1.10 REST OF MIDDLE EAST AND AFRICA 290

17 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE 291

  • 17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 291

18 SWOT ANALYSIS 292

19 COMPANY PROFILE 293

  • 19.1 CANON MEDICAL SYSTEMS CORPORATION 293
    • 19.1.1 COMPANY SNAPSHOT 293
    • 19.1.2 REVENUE ANALYSIS 293
    • 19.1.3 COMPANY PROFILE 294
    • 19.1.4 PRODUCT PORTFOLIO 294
    • 19.1.5 RECENT DEVELOPMENT 294
  • 19.2 KONINKLIJKE PHILIPS N.V. 295
    • 19.2.1 COMPANY SNAPSHOT 295
    • 19.2.2 REVENUE ANALYSIS 295
    • 19.2.3 COMPANY PROFILE 296
    • 19.2.4 PRODUCT PORTFOLIO 296
    • 19.2.5 RECENT DEVELOPMENTS 297
  • 19.3 GENERAL ELECTRIC COMPANY 298
    • 19.3.1 COMPANY SNAPSHOT 298
    • 19.3.2 REVENUE ANALYSIS 298
    • 19.3.3 COMPANY PROFILE 299
    • 19.3.4 PRODUCT PORTFOLIO 299
    • 19.3.5 RECENT DEVELOPMENTS 300
  • 19.4 SIEMENS HEALTHCARE GMBH 301
    • 19.4.1 COMPANY SNAPSHOT 301
    • 19.4.2 REVENUE ANALYSIS 301
    • 19.4.3 COMPANY PROFILE 302
    • 19.4.4 PRODUCT PORTFOLIO 302
    • 19.4.5 RECENT DEVELOPMENT 303
  • 19.5 GRAIL 304
    • 19.5.1 COMPANY SNAPSHOT 304
    • 19.5.2 PRODUCT PORTFOLIO 304
    • 19.5.3 RECENT DEVELOPMENTS 304
  • 19.6 AMBRY GENETICS 306
    • 19.6.1 COMPANY SNAPSHOT 306
    • 19.6.2 PRODUCT PORTFOLIO 306
    • 19.6.3 RECENT DEVELOPMENT 306
  • 19.7 BIOVENDOR R&D 307
    • 19.7.1 COMPANY SNAPSHOT 307
    • 19.7.2 PRODUCT PORTFOLIO 307
    • 19.7.3 RECENT DEVELOPMENT 307
  • 19.8 BLUEPRINT GENETICS OY. 308
    • 19.8.1 COMPANY SNAPSHOT 308
    • 19.8.2 PRODUCT PORTFOLIO 308
    • 19.8.3 RECENT DEVELOPMENT 308
  • 19.9 CD GENOMICS 309
    • 19.9.1 COMPANY SNAPSHOT 309
    • 19.9.2 PRODUCT PORTFOLIO 309
    • 19.9.3 RECENT DEVELOPMENT 309
  • 19.10 CENTOGENE N.V. 310
    • 19.10.1 COMPANY SNAPSHOT 310
    • 19.10.2 REVENUE ANALYSIS 310
    • 19.10.3 PRODUCT PORTFOLIO 311
    • 19.10.4 RECENT DEVELOPMENT 311
  • 19.11 CREATIVE DIAGNOSTICS 312
    • 19.11.1 COMPANY SNAPSHOT 312
    • 19.11.2 PRODUCT PORTFOLIO 312
    • 19.11.3 RECENT DEVELOPMENT 312
  • 19.12 FUJIFILM CORPORATION 313
    • 19.12.1 COMPANY SNAPSHOT 313
    • 19.12.2 REVENUE ANALYSIS 313
    • 19.12.3 PRODUCT PORTFOLIO 314
    • 19.12.4 RECENT DEVELOPMENTS 314
  • 19.13 GENEDX, LLC 315
    • 19.13.1 COMPANY SNAPSHOT 315
    • 19.13.2 REVENUE ANALYSIS 315
    • 19.13.3 PRODUCT PORTFOLIO 316
    • 19.13.4 RECENT DEVELOPMENT 316
  • 19.14 GENPATH, A DIVISION OF BIOREFERENCE LABORATORIES, AN OPKO HEALTH INC. COMPANY 317
    • 19.14.1 COMPANY SNAPSHOT 317
    • 19.14.2 PRODUCT PORTFOLIO 317
    • 19.14.3 RECENT DEVELOPMENT 317
  • 19.15 ILLUMINA, INC. 318
    • 19.15.1 COMPANY SNAPSHOT 318
    • 19.15.2 REVENUE ANALYSIS 318
    • 19.15.3 PRODUCT PORTFOLIO 319
    • 19.15.4 RECENT DEVELOPMENT 319
  • 19.16 INVITAE CORPORATION 320
    • 19.16.1 COMPANY SNAPSHOT 320
    • 19.16.2 REVENUE ANALYSIS 320
    • 19.16.3 PRODUCT PORTFOLIO 321
    • 19.16.4 RECENT DEVELOPMENT 321
  • 19.17 LABORATORY CORPORATION OF AMERICA HOLDINGS 322
    • 19.17.1 COMPANY SNAPSHOT 322
    • 19.17.2 REVENUE ANALYSIS 322
    • 19.17.3 PRODUCT PORTFOLIO 323
    • 19.17.4 RECENT DEVELOPMENTS 323
  • 19.18 MYRIAD GENETICS, INC. 324
    • 19.18.1 COMPANY SNAPSHOT 324
    • 19.18.2 REVENUE ANALYSIS 324
    • 19.18.3 PRODUCT PORTFOLIO 325
    • 19.18.4 RECENT DEVELOPMENT 325
  • 19.19 THERMO FISHER SCIENTIFIC INC. 326
    • 19.19.1 COMPANY SNAPSHOT 326
    • 19.19.2 REVENUE ANALYSIS 326
    • 19.19.3 PRODUCT PORTFOLIO 327
    • 19.19.4 RECENT DEVELOPMENT 327
  • 19.20 QIAGEN 328
    • 19.20.1 COMPANY SNAPSHOT 328
    • 19.20.2 REVENUE ANALYSIS 328
    • 19.20.3 PRODUCT PORTFOLIO 329
    • 19.20.4 RECENT DEVELOPMENT 329

20 QUESTIONNAIRE 330

21 RELATED REPORTS 334

LIST OF TABLES

  • TABLE 1 ESTIMATED NEW CANCER CASES AND DEATHS 68
  • TABLE 2 APPROVED DIAGNOSTICS OF KIDNEY CANCER 70
  • TABLE 3 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 81
  • TABLE 4 MIDDLE EAST & AFRICA IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 82
  • TABLE 5 MIDDLE EAST & AFRICA IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 83
  • TABLE 6 MIDDLE EAST & AFRICA BLOOD TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 84
  • TABLE 7 MIDDLE EAST & AFRICA BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 85
  • TABLE 8 MIDDLE EAST & AFRICA BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 85
  • TABLE 9 MIDDLE EAST & AFRICA BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 86
  • TABLE 10 MIDDLE EAST & AFRICA BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 87
  • TABLE 11 MIDDLE EAST & AFRICA GENETIC TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 88
  • TABLE 12 MIDDLE EAST & AFRICA OTHERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 89
  • TABLE 13 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 93
  • TABLE 14 MIDDLE EAST & AFRICA STAGE I IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 94
  • TABLE 15 MIDDLE EAST & AFRICA STAGE II IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 95
  • TABLE 16 MIDDLE EAST & AFRICA STAGE III IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 95
  • TABLE 17 MIDDLE EAST & AFRICA STAGE IV IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 96
  • TABLE 18 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 101
  • TABLE 19 MIDDLE EAST & AFRICA RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 102
  • TABLE 20 MIDDLE EAST & AFRICA RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 103
  • TABLE 21 MIDDLE EAST & AFRICA CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 104
  • TABLE 22 MIDDLE EAST & AFRICA CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 104
  • TABLE 23 MIDDLE EAST & AFRICA NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 106
  • TABLE 24 MIDDLE EAST & AFRICA NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 106
  • TABLE 25 MIDDLE EAST & AFRICA PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 106
  • TABLE 26 MIDDLE EAST & AFRICA CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 107
  • TABLE 27 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 113
  • TABLE 28 MIDDLE EAST & AFRICA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 114
  • TABLE 29 MIDDLE EAST & AFRICA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 115
  • TABLE 30 MIDDLE EAST & AFRICA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 115
  • TABLE 31 MIDDLE EAST & AFRICA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 115
  • TABLE 32 MIDDLE EAST & AFRICA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 116
  • TABLE 33 MIDDLE EAST & AFRICA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 117
  • TABLE 34 MIDDLE EAST & AFRICA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 117
  • TABLE 35 MIDDLE EAST & AFRICA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 117
  • TABLE 36 MIDDLE EAST & AFRICA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 119
  • TABLE 37 MIDDLE EAST & AFRICA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 119
  • TABLE 38 MIDDLE EAST & AFRICA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 119
  • TABLE 39 MIDDLE EAST & AFRICA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 119
  • TABLE 40 MIDDLE EAST & AFRICA OTHER CONSUMABLES IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 120
  • TABLE 41 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 124
  • TABLE 42 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 125
  • TABLE 43 MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 126
  • TABLE 44 MIDDLE EAST & AFRICA FLUORIMMUNOASSAY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 127
  • TABLE 45 MIDDLE EAST & AFRICA COMPARATIVE GENOMIC HYBRIDIZATION IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 127
  • TABLE 46 MIDDLE EAST & AFRICA IMMUNOHISTOCHEMICAL IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 128
  • TABLE 47 MIDDLE EAST & AFRICA OTHERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 129
  • TABLE 48 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 133
  • TABLE 49 MIDDLE EAST & AFRICA SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 134
  • TABLE 50 MIDDLE EAST & AFRICA SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 134
  • TABLE 51 MIDDLE EAST & AFRICA DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 136
  • TABLE 52 MIDDLE EAST & AFRICA DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 136
  • TABLE 53 MIDDLE EAST & AFRICA PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 137
  • TABLE 54 MIDDLE EAST & AFRICA PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 137
  • TABLE 55 MIDDLE EAST & AFRICA RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 139
  • TABLE 56 MIDDLE EAST & AFRICA RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 139
  • TABLE 57 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 144
  • TABLE 58 MIDDLE EAST & AFRICA HOSPITALS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 145
  • TABLE 59 MIDDLE EAST & AFRICA DIAGNOSTIC CENTERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 146
  • TABLE 60 MIDDLE EAST & AFRICA CANCER RESEARCH CENTERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 146
  • TABLE 61 MIDDLE EAST & AFRICA ACADEMIC INSTITUTES IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 147
  • TABLE 62 MIDDLE EAST & AFRICA AMBULATORY SURGICAL CENTERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 148
  • TABLE 63 MIDDLE EAST & AFRICA OTHERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 148
  • TABLE 64 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 152
  • TABLE 65 MIDDLE EAST & AFRICA DIRECT TENDER IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 153
  • TABLE 66 MIDDLE EAST & AFRICA RETAIL SALES IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 154
  • TABLE 67 MIDDLE EAST & AFRICA OTHERS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION) 154
  • TABLE 68 MIDDLE EAST AND AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 161
  • TABLE 69 MIDDLE EAST AND AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 161
  • TABLE 70 MIDDLE EAST AND AFRICA IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 161
  • TABLE 71 MIDDLE EAST AND AFRICA BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 162
  • TABLE 72 MIDDLE EAST AND AFRICA BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 162
  • TABLE 73 MIDDLE EAST AND AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION) 162
  • TABLE 74 MIDDLE EAST AND AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 162
  • TABLE 75 MIDDLE EAST AND AFRICA RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 163
  • TABLE 76 MIDDLE EAST AND AFRICA CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 163
  • TABLE 77 MIDDLE EAST AND AFRICA NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 163
  • TABLE 78 MIDDLE EAST AND AFRICA PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 163
  • TABLE 79 MIDDLE EAST AND AFRICA CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 164
  • TABLE 80 MIDDLE EAST AND AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 164
  • TABLE 81 MIDDLE EAST AND AFRICA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 164
  • TABLE 82 MIDDLE EAST AND AFRICA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 164
  • TABLE 83 MIDDLE EAST AND AFRICA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 164
  • TABLE 84 MIDDLE EAST AND AFRICA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 165
  • TABLE 85 MIDDLE EAST AND AFRICA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 165
  • TABLE 86 MIDDLE EAST AND AFRICA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 165
  • TABLE 87 MIDDLE EAST AND AFRICA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 165
  • TABLE 88 MIDDLE EAST AND AFRICA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 165
  • TABLE 89 MIDDLE EAST AND AFRICA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 166
  • TABLE 90 MIDDLE EAST AND AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 166
  • TABLE 91 MIDDLE EAST AND AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 166
  • TABLE 92 MIDDLE EAST AND AFRICA SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 166
  • TABLE 93 MIDDLE EAST AND AFRICA DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 167
  • TABLE 94 MIDDLE EAST AND AFRICA PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 167
  • TABLE 95 MIDDLE EAST AND AFRICA RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 167
  • TABLE 96 MIDDLE EAST AND AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 167
  • TABLE 97 MIDDLE EAST AND AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 168
  • TABLE 98 SOUTH AFRICA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 169
  • TABLE 99 SOUTH AFRICA IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 169
  • TABLE 100 SOUTH AFRICA BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 169
  • TABLE 101 SOUTH AFRICA BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 170
  • TABLE 102 SOUTH AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 170
  • TABLE 103 SOUTH AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 170
  • TABLE 104 SOUTH AFRICA RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 170
  • TABLE 105 SOUTH AFRICA CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 171
  • TABLE 106 SOUTH AFRICA NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 171
  • TABLE 107 SOUTH AFRICA PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 171
  • TABLE 108 SOUTH AFRICA CHROMPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 171
  • TABLE 109 SOUTH AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 172
  • TABLE 110 SOUTH AFRICA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 172
  • TABLE 111 SOUTH AFRICA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 172
  • TABLE 112 SOUTH AFRICA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 172
  • TABLE 113 SOUTH AFRICA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 172
  • TABLE 114 SOUTH AFRICA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 173
  • TABLE 115 SOUTH AFRICA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 173
  • TABLE 116 SOUTH AFRICA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 173
  • TABLE 117 SOUTH AFRICA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 173
  • TABLE 118 SOUTH AFRICA KITS AND REAGENTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 173
  • TABLE 119 SOUTH AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION) 174
  • TABLE 120 SOUTH AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 174
  • TABLE 121 SOUTH AFRICA SCREENING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 174
  • TABLE 122 SOUTH AFRICA DIAGNOSTIC AND PREDICTIVE IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 174
  • TABLE 123 SOUTH AFRICA PROGNOSTIC IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 175
  • TABLE 124 SOUTH AFRICA RESEARCH IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 175
  • TABLE 125 SOUTH AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION) 175
  • TABLE 126 SOUTH AFRICA KIDNEY CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION) 175
  • TABLE 127 SAUDI ARABIA KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 176
  • TABLE 128 SAUDI ARABIA IMAGING IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 176
  • TABLE 129 SAUDI ARABIA BIOPSY IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 176
  • TABLE 130 SAUDI ARABIA BIOMARKER TEST IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 177
  • TABLE 131 SAUDI ARABIA KIDNEY CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION) 177
  • TABLE 132 SAUDI ARABIA KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 177
  • TABLE 133 SAUDI ARABIA RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 177
  • TABLE 134 SAUDI ARABIA CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 178
  • TABLE 135 SAUDI ARABIA NON CLEAR CELL RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TUMOR TYPE, 2021-2030 (USD MILLION) 178
  • TABLE 136 SAUDI ARABIA PAPILLARY RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 178
  • TABLE 137 SAUDI ARABIA CHROMOPHOBE RENAL CELL CARCINOMA IN KIDNEY CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION) 179
  • TABLE 138 SAUDI ARABIA KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 179
  • TABLE 139 SAUDI ARABIA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 179
  • TABLE 140 SAUDI ARABIA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 179
  • TABLE 141 SAUDI ARABIA INSTRUMENT BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD) 180
  • TABLE 142 SAUDI ARABIA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION) 180
  • TABLE 143 SAUDI ARABIA PLATFORM BASED PRODUCTS IN KIDNEY CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (UNITS) 180

LIST OF FIGURES

  • FIGURE 1 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET: SEGMENTATION 39
  • FIGURE 2 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION 42
  • FIGURE 3 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET: DROC ANALYSIS 43
  • FIGURE 4 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS 44
  • FIGURE 5 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS 44
  • FIGURE 6 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS 45
  • FIGURE 7 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET: MARKET APPLICATION COVERAGE GRID 47
  • FIGURE 8 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID 49
  • FIGURE 9 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS 50
  • FIGURE 10 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET: SEGMENTATION 54
  • FIGURE 11 GROWING AWARENESS OF KIDNEY CANCER AND INCREASING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE GROWTH OF THE MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET FROM 2023 TO 2030 55
  • FIGURE 12 THE IMAGING TEST SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET IN 2023 & 2030 55
  • FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET 66
  • FIGURE 14 KIDNEY CANCER INCIDENCE, BOTH SEXES, BY REGION (2020) 68
  • FIGURE 15 KIDNEY CANCER MORTALITY, BOTH SEXES, BY REGION (2020) 68
  • FIGURE 16 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY TEST TYPE, 2022 78
  • FIGURE 17 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY TEST TYPE, 2023-2030 (USD MILLION) 79
  • FIGURE 18 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY TEST TYPE, CAGR (2023-2030) 79
  • FIGURE 19 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY TEST TYPE, LIFELINE CURVE 80
  • FIGURE 20 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY CANCER STAGE , 2022 90
  • FIGURE 21 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY CANCER STAGE, 2023-2030 (USD MILLION) 91
  • FIGURE 22 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY CANCER STAGE, CAGR (2023-2030) 91
  • FIGURE 23 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY CANCER STAGE, LIFELINE CURVE 92
  • FIGURE 24 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY TUMOR TYPE, 2022 98
  • FIGURE 25 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY TUMOR TYPE, 2023-2030 (USD MILLION) 99
  • FIGURE 26 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY TUMOR TYPE, CAGR (2023-2030) 99
  • FIGURE 27 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY TUMOR TYPE, LIFELINE CURVE 100
  • FIGURE 28 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY PRODUCT, 2022 110
  • FIGURE 29 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY PRODUCT, 2023-2030 (USD MILLION) 111
  • FIGURE 30 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY PRODUCT, CAGR (2023-2030) 111
  • FIGURE 31 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY PRODUCT, LIFELINE CURVE 112
  • FIGURE 32 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY TECHNOLOGY, 2022 121
  • FIGURE 33 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY TECHNOLOGY, 2023-2030 (USD MILLION) 122
  • FIGURE 34 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY TECHNOLOGY, CAGR (2023-2030) 122
  • FIGURE 35 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY TECHNOLOGY, LIFELINE CURVE 123
  • FIGURE 36 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY APPLICATION, 2022 130
  • FIGURE 37 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY APPLICATION, 2023-2030 (USD MILLION) 131
  • FIGURE 38 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY APPLICATION, CAGR (2023-2030) 131
  • FIGURE 39 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY APPLICATION, LIFELINE CURVE 132
  • FIGURE 40 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY END USER, 2022 141
  • FIGURE 41 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY END USER, 2023-2030 (USD MILLION) 142
  • FIGURE 42 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY END USER, CAGR (2023-2030) 142
  • FIGURE 43 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY END USER, LIFELINE CURVE 143
  • FIGURE 44 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2022 149
  • FIGURE 45 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION) 150
  • FIGURE 46 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 150
  • FIGURE 47 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE 151
  • FIGURE 48 MIDDLE EAST AND AFRICA KIDNEY CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022) 156
  • FIGURE 49 MIDDLE EAST AND AFRICA KIDNEY CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022) 158
  • FIGURE 50 MIDDLE EAST AND AFRICA KIDNEY CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030) 158
  • FIGURE 51 MIDDLE EAST AND AFRICA KIDNEY CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030) 159
  • FIGURE 52 MIDDLE EAST AND AFRICA KIDNEY CANCER DIAGNOSTICS MARKET: TEST TYPE (2023-2030) 159
  • FIGURE 53 MIDDLE EAST & AFRICA KIDNEY CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%) 239
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!